A trial of three regimens to prevent tuberculosis in ugandan adults infected with the human immunodeficiency virus

New England Journal of Medicine

Volumn 337, Issue 12, 1997, Pages 801-808

  Whalen, Christopher C ^a,b,g   Johnson, John L ^a   Okwera, Alphonse ^c   Hom, David L ^a   Huebner, Robin ^f   Mugyenyi, Peter ^d   Mugerwa, Roy D ^e   Ellner, Jerrold J ^a   Nsuhuga, Peter ^c   Vjecha, Michael ^a   Myanja, Harriet ^e   Kityo, Cissy ^d   Loughlin, Anita ^a   Milberg, John ^a   Pekovic, Vukosava ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINISTRY OF HEALTH   (Uganda)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e MAKERERE UNIVERSITY   (Uganda)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; TREATMENT OUTCOME; TUBERCULOSIS; UGANDA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN; RISK; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 9844267960     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199709183371201     Document Type: Article

References (38)

1. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuberc Lung Dis 1992;73:311-21.
2. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
3. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268:504-9. [Erratum, JAMA 1992;268: 3434.]
4. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345-9.
5. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 1995;274:143-8.
6. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis: the Makerere University-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1996;153:1977-81.
7. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991;144:750-5.
8. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6 month) mortality. Am Rev Respir Dis 1992;146:849-54.
9. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987;136:570-4.
10. Small PM. Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-94.
11. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mor tality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995;345:607-10.
12. Pitchenik AE. Tuberculosis control and the AIDS epidemic in developing countries. Ann Intern Med 1990;113:89-91.
13. O'Brien RJ, Perriens JH. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS 1995;9:665-73.
14. Goodgame RW. AIDS in Uganda - clinical and social features. N Engl J Med 1990;323:383-9.
15. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993;119:194-8.
16. Graham NMH, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996; 156:889-94.
17. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979;139:337-9.
18. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
19. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/ British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
20. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64.
21. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
22. The use of preventive therapy for tuberculous infection in the United States. MMWR 1990;39(RR-8):9-12.
23. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4.
24. Pozniak AL, MacLeod GA, Mahari M, Legg W, Weinberg J. The influence of HIV status on single and multiple drug reactions to antituberculous therapy in Africa. AIDS 1992;6:809-14.
25. Karnofsky DH, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:191-205.
26. Bass JB Jr, Farer LS, Hopewell PC, Jacobs RF, Snider DE Jr. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990; 142:725-35. [Erratum, Am Rev Respir Dis 1990;142:1470.]
27. AIDS Clinical Trials Group. Table for grading severity of adult adverse experiences. Washington, D.C.: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1993.
28. International Union Against Tuberculosis and Lung Disease. Technical guide for sputum examination for tuberculosis by direct microscopy. Bull Int Union Against Tuberc Lung Dis 1986;61:1-16.
29. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
30. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
31. De Cock KM, Grant A, Porter JDH. Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 1995;345:833-6.
32. Halsey N, Coberly J, Atkinson J, et al. Twice weekly INH for TB prophylaxis. In: Abstracts of the 10th International Conference on AIDS/International Conference on STD, Yokohama, Japan, August 7-12, 1994: 167. abstract.
33. Wadhawan D, Hira S, Mwansa N, Perine P. Preventive tuberculosis chemotherapy with isoniazid among persons infected with human immunodeficiency virus. In: Abstracts of the Seventh International Conference on AIDS, Florence, Italy, June 6-21, 1991. Vol. 2. Rome: Istituto Superiore di Sanità, 1991:247. abstract.
34. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93.
35. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993;329:1122-3.
36. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327:1817-8.
37. Patel KB, Belmonte R, Crowe HM. Drag malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995;332:336-7.
38. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis 1975;111:573-7.